Table 1.
Patient Characteristics (n=77)
| pBM Group | aBM Group | |
|---|---|---|
| Characteristic | Total (n=69) | Total (n=8) |
| Gender, n (%) | ||
| Male | 51 (73.9%) | 6 (75%) |
| Female | 18 (26.1%) | 2 (15%) |
| Age, median | ||
| <70 | 62 (89.9%) | 5 (62.5%) |
| ≧70 | 7 (10.1%) | 3 (37.5%) |
| Smoking status, n (%) | ||
| Non-Smoker | 40 (58%) | 6 (75%) |
| Smoker | 29 (42%) | 2 (15%) |
| ECOG PS | ||
| 0–1 | 53 (76.8%) | 1 (12.5%) |
| ≥2 | 16 (23.2%) | 7 (87.5%) |
| Tumor Histology | ||
| Adenocarcinoma | 47 (68.1%) | 6 (75%) |
| Squamous cell carcinoma | 8 (11.6%) | 2 (15%) |
| Other | 14 (20.3%) | 0 |
| Mutation | ||
| No-mutation | 48(69.6%) | 6 (75%) |
| EGFR mutation | 12(17.4%) | 2 (15%) |
| KRAS mutation | 6(8.7%) | 0 |
| ALK mutation | 2(2.9%) | 0 |
| ROS1 mutation | 1(1.4%) | 0 |
| PD-L1 expression | ||
| NO-detected | 46(66.7%) | 4 (50%) |
| 0 | 14(20.3%) | 4 (50%) |
| 1–50% | 5(7.2%) | |
| ≥50% | 4(5.8%) | |
| Number of prior systemic therapy regimens before ICIs | ||
| 1 | 19(27.5%) | 2 (25%) |
| 2 | 12(17.4%) | 1 (12.5%) |
| ≥3 | 38(55.1%) | 5 (62.5%) |
| Liver metastases | ||
| Yes | 3 (4.3%) | 1 (12.5%) |
| No | 66 (95.7%) | 7 (87.5%) |
| Radiotherapy | ||
| NO-Radiotherapy | 28 (40.6%) | 0 |
| WBRT | 29 (42%) | 3 (37.5%) |
| SRS | 12 (17.4%) | 5 (62.5%) |
| ICIs regimes | ||
| Monotherapy | 30 (43.5%) | 4 (50%) |
| Chemotherapy | 29 (42%) | 2 (25%) |
| Anti-angiogenic therapy | 10 (14.5%) | 2 (25%) |
Abbreviations: ICI, immune checkpoint inhibitor; PD-L1, programmed death-ligand 1; WBRT, whole brain radiotherapy; SRS, stereotactic radiosurgery; pBM, patients with brain metastasis prior to ICIs treatment; aBM group, patients with brain metastasis after ICIs treatment.